• Immunome, Inc. recently dosed the first patient in a Phase 1, first-in-human trial of IM-1617, a potential first-in-class antibody-drug conjugate using its proprietary HC74 TOP1 inhibitor payload in advanced solid tumors such as colorectal, non-small cell lung, and breast cancer.
• This trial not only marks Immunome’s initial entry into human testing for its solid tumor ADC platform but also highlights progress toward a broader ADC pipeline, with investigational new drug submissions for IM-1340 and IM-1335 planned in 2026.
• We’ll examine how advancing IM-1617 into first-in-human testing, leveraging Immunome’s proprietary HC74 TOP1 inhibitor, may influence the company’s investment narrative.

Find 43 companies with promising cash flow potential yet trading below their fair value.

What Is Immunome's Investment Narrative?

To own Immunome today, you need to believe in its transition from a loss-making R&D story into a company with clinically validated assets across both rare disease and oncology. The recent first-patient dosing of IM-1617 fits neatly into that picture, reinforcing the idea that Immunome is building a genuine ADC franchise around its HC74 TOP1 payload, rather than a single-asset bet on varegacestat. In the near term, the key catalyst still looks like the FDA’s review of the varegacestat NDA for desmoid tumors, but IM-1617’s move into the clinic modestly upgrades the importance of ADC data readouts as secondary drivers. At the same time, it also sharpens existing risks: persistent losses, ongoing cash burn after a US$400,000,000 raise, and the possibility of further dilution if clinical milestones slip.

However, one risk around future funding needs may catch new shareholders off guard. Despite retreating, Immunome's shares might still be trading above their fair value and there could be some more downside. Discover how much.

Exploring Other Perspectives

Community members on Simply Wall St place Immunome’s fair value between about US$35 and a very large US$156, across 2 separate views. That spread sits against a business still posting over US$200,000,000 in annual losses and leaning heavily on future trial and regulatory outcomes. You can weigh these contrasting expectations for yourself by looking closely at both the ADC pipeline news and the company’s cash requirements.

Explore 2 other fair value estimates on Immunome - why the stock might be worth over 8x more than the current price!

Decide For Yourself

Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Immunome research is our analysis highlighting 3 key rewards and 4 important warning signs that could impact your investment decision.
• Our free Immunome research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Immunome's overall financial health at a glance.

Contemplating Other Strategies?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.
• We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Capitalize on the AI infrastructure supercycle with our selection of the 48 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.